In another study, Pozzi et al. analyzed 122 AML patients with available WT1 evaluations before and after Allo-SCT, finding a higher relapse rate (54%) in patients with WT1 overexpression (exceeding 100 copies/104 ABL) at any time post-SCT, as compared to patients with post-Allo-SCT WT1 expression <100 copies (16%, p < 0.0001) [43]. The gene discussed is WT1; the disease is acute myeloid leukemia.